4.3 Review

Long-Term Treatment of Postmenopausal Osteoporosis

期刊

ENDOCRINOLOGY AND METABOLISM
卷 36, 期 3, 页码 544-552

出版社

KOREAN ENDOCRINE SOC
DOI: 10.3803/EnM.2021.301

关键词

Osteoporosis, postmenopausal; Diphosphonates; Denosumab; Duration of therapy

向作者/读者索取更多资源

Osteoporosis is a chronic condition that cannot be cured, with a major gap in primary prevention of fractures. Case finding strategies and pharmacological interventions are available to provide lifelong fracture protection, with the benefits of osteoporosis therapies far outweighing the rare risks.
Osteoporosis is an incurable chronic condition, like heart disease, diabetes, or hypertension. A large gap currently exists in the primary prevention of fractures, and studies show that an estimated 80% to 90% of adults do not receive appropriate osteoporosis management even in the secondary prevention setting. Case finding strategies have been developed and effective pharmacological interventions are available. This publication addresses how best to use the pharmacological options available for postmenopausal osteoporosis to provide lifelong fracture protection in patients at high and very high risk of fracture. The benefit of osteoporosis therapies far outweighs the rare risks.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据